Skip to content
Clinical Trials – home

Klinički bolnički centar Zagreb (University Hospital Center Zagreb)

Verified siteinfo

Croatia Vinogradska Cesta 29, Zagreb, 10000 Zagreb, Croatia

  • 17 trials recruiting
  • Non-small cell lung cancer · Non-small cell lung cancer metastatic · Renal cell carcinoma
  • Adults and children

About Specializations

Klinički bolnički centar Zagreb (University Hospital Center Zagreb) in Zagreb, Croatia specialises in clinical trials of conditions such as Non-small cell lung cancer, Non-small cell lung cancer metastatic, Renal cell carcinoma, Dermatitis atopic, and other specialisations. This site conducts important research.

Main research areas of the site

Neurology and Epilepsy Research

The medical center is at the forefront of neurology research, with a particular focus on epilepsy. The institution is dedicated to advancing the understanding and treatment of refractory focal onset epilepsy, a challenging condition that requires innovative therapeutic approaches.

  • Refractory Focal Onset Epilepsy
  • Seizure Reduction Strategies
  • Adjunctive Therapy Development

Through its cutting-edge research, the center contributes significantly to the development of new therapies that aim to improve the quality of life for patients with difficult-to-treat epilepsy. The ongoing studies are pivotal in exploring the efficacy and safety of novel treatments, thereby setting new standards in clinical applications.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Vinogradska Cesta 29, Zagreb10000 ZagrebCroatia
Recruiting now
17 trials
Conditions studied
41
Partner status
Verified site

More sites in ZagrebCroatia

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

50 clinical trials

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC

Bronchiectasis

Recruiting

Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:BI 1291583
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Safety of BHV-7000 for Adults with Hard-to-Treat Focal Onset Epilepsy

InvestigationalNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:BHV-7000
  • Sponsor:Biohaven Therapeutics Ltd.

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:CroatiaCroatia
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Rifabutin plus drug combination for adult patients with hospital‑acquired and ventilator‑associated pneumonia caused by carbapenem‑resistant Acinetobacter baumannii

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Ampicillin Sodium
  • Sponsor:Bioversys S.A.S.

A study on the effectiveness of cagrilintide and semaglutide for weight management in children and adolescents with obesity

Investigational
Countries:CroatiaCroatia
  • Participants:0–17 years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

A study to evaluate the effectiveness and safety of remibrutinib in patients with secondary progressive multiple sclerosis

Investigational
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Remibrutinib
  • Sponsor:Novartis Pharma AG

A Study of Belzutifan and Zanzalintinib Compared to Cabozantinib in Patients with Advanced Kidney Cancer that Returned After Previous Treatment

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Biogen Idec Research Limited
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Study on the Effects of Darolutamide and Drug Combination for Patients with Metastatic Hormone-Naïve Prostate Cancer

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:European Organisation For Research And Treatment Of Cancer
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.